Literature DB >> 16642017

A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva.

Eileen M Shore1, Meiqi Xu, George J Feldman, David A Fenstermacher, Tae-Joon Cho, In Ho Choi, J Michael Connor, Patricia Delai, David L Glaser, Martine LeMerrer, Rolf Morhart, John G Rogers, Roger Smith, James T Triffitt, J Andoni Urtizberea, Michael Zasloff, Matthew A Brown, Frederick S Kaplan.   

Abstract

Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disorder of skeletal malformations and progressive extraskeletal ossification. We mapped FOP to chromosome 2q23-24 by linkage analysis and identified an identical heterozygous mutation (617G --> A; R206H) in the glycine-serine (GS) activation domain of ACVR1, a BMP type I receptor, in all affected individuals examined. Protein modeling predicts destabilization of the GS domain, consistent with constitutive activation of ACVR1 as the underlying cause of the ectopic chondrogenesis, osteogenesis and joint fusions seen in FOP.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16642017     DOI: 10.1038/ng1783

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  459 in total

1.  BMP3 suppresses osteoblast differentiation of bone marrow stromal cells via interaction with Acvr2b.

Authors:  Shoichiro Kokabu; Laura Gamer; Karen Cox; Jonathan Lowery; Kunikazu Tsuji; Regina Raz; Aris Economides; Takenobu Katagiri; Vicki Rosen
Journal:  Mol Endocrinol       Date:  2011-11-10

2.  Fibrodysplasia ossificans progressiva: a human genetic disorder of extraskeletal bone formation, or--how does one tissue become another?

Authors:  Eileen M Shore
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2012 Jan-Feb       Impact factor: 5.814

3.  Multipotent progenitors resident in the skeletal muscle interstitium exhibit robust BMP-dependent osteogenic activity and mediate heterotopic ossification.

Authors:  Michael N Wosczyna; Arpita A Biswas; Catherine A Cogswell; David J Goldhamer
Journal:  J Bone Miner Res       Date:  2012-05       Impact factor: 6.741

4.  Picking a bone with heterotopic ossification: translational progress current and future.

Authors:  Jonathan R Peterson; Shailesh Agarwal; Shawn J Loder; Oluwatobi Eboda; Paul S Cederna; Steven R Buchman; Chuanwu Xi; Stewart C Wang; Benjamin Levi
Journal:  Ann Transl Med       Date:  2015-08

Review 5.  Fibrodysplasia ossificans progressiva (FOP): A disorder of osteochondrogenesis.

Authors:  Frederick S Kaplan; Mona Al Mukaddam; Alexandra Stanley; O Will Towler; Eileen M Shore
Journal:  Bone       Date:  2020-07-27       Impact factor: 4.398

6.  Rapid and reliable healing of critical size bone defects with genetically modified sheep muscle.

Authors:  F Liu; E Ferreira; R M Porter; V Glatt; M Schinhan; Z Shen; M A Randolph; C A Kirker-Head; C Wehling; M S Vrahas; C H Evans; J W Wells
Journal:  Eur Cell Mater       Date:  2015-09-21       Impact factor: 3.942

Review 7.  Cellular and morphological aspects of fibrodysplasia ossificans progressiva. Lessons of formation, repair, and bone bioengineering.

Authors:  Anderson Martelli; Arnaldo Rodrigues Santos
Journal:  Organogenesis       Date:  2014-10-31       Impact factor: 2.500

8.  De novo 617G-A nucleotide mutation in the ACVR1 gene in a Taiwanese patient with fibrodysplasia ossificans progressiva.

Authors:  Gau-Tyan Lin; Hsueh-Wei Chang; Chih-Shan Liu; Peng-Ju Huang; Hsien-Chung Wang; Yuh-Min Cheng
Journal:  J Hum Genet       Date:  2006-11-01       Impact factor: 3.172

9.  Pregnancy in fibrodysplasia ossificans progressiva.

Authors:  Javaid A Muglu; Aditya Garg; T Pandiarajan; Eileen M Shore; Frederick S Kaplan; Dhiraj Uchil; Malcolm J Dickson
Journal:  Obstet Med       Date:  2011-12-08

Review 10.  Emerging roles of the bone morphogenetic protein pathway in cancer: potential therapeutic target for kinase inhibition.

Authors:  Pawina Jiramongkolchai; Philip Owens; Charles C Hong
Journal:  Biochem Soc Trans       Date:  2016-08-15       Impact factor: 5.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.